Citation only
via Europe PMC
Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies.
Brooks HW, Cusick NC, Wu S, Farr JN.
Best practice & research. Clinical rheumatology · 2026
Abstract
Osteoporosis therapeutics have advanced from antiresorptive drugs that slow bone loss to osteoanabolic and dual-action agents that can rapidly rebuild skeletal integrity and reduce fracture risk. Yet the current anabolic era leaves important clinical questions unresolved: why responses vary among older adults, why gains are transient, how best to sequence therapy, and how to sustain skeletal resilience in the biologically aged bone microenvironment. Cellular senescence(definition) has emerged as a plausible mechanistic bridge linking skeletal aging, chronic inflammation, impaired osteoblastogenesis, increased osteoclastogenesis, marrow adiposity, diabetes-associated fragility, and delayed repair. Preclinical studies show that senescent-cell clearance can prevent or partially reverse age-related bone loss, while early human senolytic data suggest that skeletal response may depend on baseline senescent-cell burden. This review discusses current anabolic therapies, the rationale for senescence-targeted approaches, and future biomarker-informed strategies to integrate anabolic induction, antiresorptive consolidation, and experimental modulation of skeletal aging biology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1016/j.berh.2026.102203
- Canonical
- link ↗
- Fetched
- 2026-10-22 MST
Cite this
APA
HW, B., NC, C., S, W., & JN., F. (2026). Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies. <em>Best practice & research. Clinical rheumatology</em>. https://doi.org/10.1016/j.berh.2026.102203
Vancouver
HW B, NC C, S W, JN. F. Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies. Best practice & research. Clinical rheumatology. 2026. doi:10.1016/j.berh.2026.102203.
BibTeX
@article{brooks2026Future,
title = {Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies.},
author = {Brooks HW and Cusick NC and Wu S and Farr JN.},
journal = {Best practice & research. Clinical rheumatology},
year = {2026},
doi = {10.1016/j.berh.2026.102203},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in immunology 2026
Open access · OA
Lymphatic vascular aging and age-related bone loss: current status and future perspectives.
Mechanisms of Ageing and Development 2021
Preprint · OA
Skeletal muscle aging, cellular senescence, and senotherapeutics: Current knowledge and future directions
CA A Cancer Journal for Clinicians 2011
Open access · OA
Aging and osteoporosis in breast and prostate cancer
Elsevier eBooks 2006
Citation only
Age-Related Osteoporosis and Skeletal Markers of Bone Turnover
Journal of Evolutionary Biochemistry and Physiology 2025
Citation only
Cellular Senescence in Skeletal Muscle: Age, Sarcopenia, Therapy
International journal of molecular sciences 2026
Open access · OA